Abstract
Taxol has activity in the treatment of high grade gliomas but estramustine phosphate (EMP) has not been used in this setting. In vitro data demonstrates that EMP is cytotoxic to glioma cell lines and estramustine binding proteins are expressed by glioma cells. The combination of Taxol and EMP is reported to be active in the treatment of hormone-refractory prostate cancer and in taxane-resistant breast and ovarian cancer. We therefore performed a phase II study to assess the activity and toxicity of this combination in high grade gliomas. Taxol was given at a dose of 225 mg/m2 intravenously over three hours on day 1 and EMP was given at a dose of 900 mg/m2 orally on days 1 through 3. Cycles were repeated every three weeks. Twenty patients with recurrent glioblastoma multiforme (GBM) were enrolled: 11 male, median age 45 years. All patients received anti-epileptic medications and 17 (80%) had received prior chemotherapy. Of 18 evaluable patients, two had partial responses (11%) and six had stable disease (33%) for a minimum of eight weeks. Treatment was well tolerated with grade 3 neutropenia occurring in only three patients. There were no other grade 3 or 4 toxicities. The median time to progression for the cohort was only six weeks (range 3–60+ weeks). The median overall survival was 12 weeks (range 3–60+ weeks). In conclusion, the combination of Taxol and EMP is well tolerated and has modest activity in the treatment of recurrent GBM.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
American Cancer Society, SEER Statistics. 1999
Grossman SA, Norris LK: Adjuvant and neoadjuvant treatment for primary brain tumors in adults. Semin Oncol 22: 530-539, 1995
Burton E, Prados M: New chemotherapy options for the treatment of malignant gliomas. Curr Opin Oncol 11: 157-161, 1999
Wong ET, Hess KR, Gleason MI, Jaekle KA, Kyritsis AP, Prados MD, Levin VA, Yung WK: Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17: 2572-2578, 1999
Chamberlain MC, Kormanik P: Salvage chemotherapy with Paclitaxel for recurrent primary brain tumors. J Clin Oncol 13: 2066-2071, 1995
Prados MD, Schold SC, Spence AM, Berger AM, McAllister LD, Mehta MP, Gilbert MR, Fulton D, Kuhn J, Lamborn K, Rector DJ, Chang SM: Phase II study of Paclitaxel in patients with recurrent malignant glioma. J Clin Oncol 14: 2316-2321, 1996
Piepmeier JM, Keefe DL, Weinstein MA, Yoshida D, Zielinski J, Lin TI, Chen Z, Naftolin F: Estramustine and estrone analogs rapidly and reversibly inhibit deoxyribonucleic acid synthesis and alter morphology in cultured human glioblastoma cells. Neurosurgery 32: 422-431, 1993
Vallbo C, Bergenheim T, Bergh A, Grankvist K, Henriksson R: DNA fragmentation induced by the antimitotic drug estramustine in malignant rat glioma but not in normal brain-suggesting an apoptotic cell death. Br J Cancer 71: 717-720, 1995
Yoshida D, Cornell-Bell A, Piepmeier JM: Selective antimitotic effects of estramustine correlate with its antimicrotubule properties on glioblastoma and astrocytes. Neurosurgery 34: 863-868, 1994
Hudes GR, Nathan FE, Khater C, Greenberg R, Gomella L, Stern C, McAleer C: Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer. Semin Oncol 22: 41-45, 1995
Speicher LA, Barone LR, Chapman AE et al.: Combined antimicrotubule activity of estramustine and Taxol in human prostatic carcinoma cell lines. Cancer Res 52: 4430-4440, 1992
Pienta KJ, Naik H, Lehr JE: Effect of estramustine, etoposide and Taxol on prostate cancer cell growth in vitro and in vivo. Urology 48: 164-170, 1996
Garcia AA, Keren-Rosenberg S, Parimoo D, Rogers M, Jeffers S, Koda R, Muggia FM: Phase I and pharmacologic study of estramustine phosphate and short infusions of paclitaxel in women with solid tumors. J Clin Oncol 16: 2959-2963, 1998
Macdonald DR, Cascino TL, Schold Jr SC, Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277-1280, 1990
Cahan MA, Walter KA, Colvin OM, Brem H: Cytotoxicity of Taxol in vitro against human and rat malignant brain tumors. Cancer Chemother Pharmacol 33: 441-444, 1994
Rowinsky EK, Donehower RC: Antimicrotubule agents. In: Chabner BA, Longpo DL (eds) Cancer Chemotherapy and Biotherapy: Principles and Practice. Lippincott-Raven, Philadelphia, 1996, pp 263-296
Bergenheim AT, Bjork P, Bergh J, von Schoultz E, Svedberg H, Henriksson R: Estramustine-binding protein and specific binding of the anti-mitotic compound estramustine in astrocytoma. Cancer Res 54: 4974-4979, 1994.
Eklov S, Mahdy E, Wester K, Bjork P, Malmstrom P, Busch C, Nilsson S: Estramustine binding protein (EMBP) content in four different cell lines and its correlation to estramustine induced metaphase arrest. Anticancer Res 16: 1819-1822, 1996
Smith CD, Zilfou JT, Zhang X, Hudes GR, Tew KD: Modulation of P-glycoprotein activity by Estramustine is limited by binding to plasma proteins. Cancer 75: 2597-2604, 1995
Huang Yang C, Shen H, Horwitz SB: Modulation of the function of P-glycoprotein by Estramustine. J Natl Cancer Inst 86: 723-725, 1994
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rosenthal, M.A., Gruber, M.L., Glass, J. et al. Phase II Study of Combination Taxol and Estramustine Phosphate in the Treatment of Recurrent Glioblastoma Multiforme. J Neurooncol 47, 59–63 (2000). https://doi.org/10.1023/A:1006426215005
Issue Date:
DOI: https://doi.org/10.1023/A:1006426215005